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Household 
Transmission of 
Carbapenemase-
producing 
Klebsiella 
pneumoniae 
To the Editor: Since its ﬁ  rst 
description in 2001, carbapenemase-
producing Klebsiella pneumoniae has 
become a frequent nosocomial patho-
gen in the eastern United States (1). 
This bacterium was introduced into 
Israel in 2005 and is endemic now in 
several hospitals in the country (2). 
We recently documented transmission 
of this organism within a household, 
the source being a debilitated patient 
who returned home after a long hos-
pitalization.
A 73-year-old man had a urologic 
procedure (transurethral resection of 
the bladder neck) in a community hos-
pital in early October 2007. He was 
initially evaluated on September 23, 
2007, at an outpatient clinic where a 
routine urine sample was obtained for 
culture. Carbapenemase-producing K. 
pneumoniae was cultured. Identiﬁ  ca-
tion and susceptibility testing of the 
isolate were completed by using the 
VITEK 2 system (bioMérieux, Marcy 
l’Etoile, France). K. pneumoniae car-
bapenemase was conﬁ  rmed by using 
the modiﬁ  ed Hodge test (3). Two re-
peat urine cultures grew the same or-
ganism; however, a stool culture was 
negative for carbapenemase-produc-
ing K. pneumoniae. 
The medical history of the patient 
included hypertension and carcinoma 
of the prostate gland that was treated 
with high-intensity focused ultrasound 
in May 2007, followed by transurethral 
resection of prostate in June 2007. The 
2 procedures were performed in 2 dif-
ferent private hospitals, and each re-
quired a 24-hour hospitalization. No 
carbapenemase-producing  K.  pneu-
moniae was documented in these hos-
pitals. Two months before detection 
of carbapenemase-producing K. pneu-
moniae, the patient received a 1-week 
course of oral amoxicillin-clavulanate 
for presumed urinary tract infection, 
although urine culture obtained on 
July 29, 2007 was sterile. A repeat 
urine culture 2 weeks later (August 
13, 2007) remained sterile.
Because the circumstances of 
strain acquisition and patient charac-
teristics were not typical for epidemi-
ology of carbapenemase-producing 
K.  pneumoniae ( 3), he was further 
questioned about possible contacts of 
relevance. The patient disclosed that 
his wife, who had amyotrophic lat-
eral sclerosis that required mechani-
cal ventilation, had been hospitalized 
in a tertiary hospital in the Tel Aviv 
area for 9 weeks until July 19, 2007. 
After discharge, she has been staying 
at home where she was cared for by 
her son, sister, and nurses; the patient 
stated that he had limited contact with 
his wife (he did not participate in her 
care). The infection control unit of 
the tertiary hospital was contacted, 
and the name of the wife was iden-
tiﬁ   ed in the hospital registry. Car-
bapenemase-producing  K.  pneumo-
niae was isolated from her urine on 
June 8, 2007.
Despite limited contact, the pa-
tient probably acquired carbapene-
mase-producing K. pneumoniae from 
his wife, who was a documented car-
rier of this organism. Because his ear-
ly urine cultures (taken after his wife 
was discharged from hospital) were 
sterile, we can assume that the trans-
mission of the organism occurred at 
their home. We cannot rule out that the 
strain was transferred by an intermedi-
ary, such as the couple’s son. It is un-
likely that the organism was acquired 
at the private hospitals from which no 
case of carbapenemase-producing K. 
pneumoniae was reported (in Israel re-
porting carbapenemase-producing K. 
pneumoniae isolates to health authori-
ties is mandatory). Also, the patient 
had 2 negative urine cultures.
Carbapenemase-producing  K. 
pneumoniae is a recent addition to the 
pool of multidrug-resistant nosoco-
mial pathogens. Most publications on 
this organism have focused on issues 
of structural and molecular epidemi-
ology. Little is known regarding clin-
ical characteristics and importance of 
infection with this organism. Until 
now, the strain has been recovered 
only from hospitalized patients with a 
longer hospital stay, those given mul-
tiple antimicrobial drug courses, and 
those mechanically ventilated (3,4). 
The strain can colonize the urinary, 
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intestinal, and respiratory tracts, as 
well as wounds; bloodstream infec-
tion is associated with higher death 
rates than infection at other sites (4). 
Hand carriage is probably the biggest 
factor in transmission of extended-
spectrum β-lactamase producers, and 
there is little evidence to suggest that 
carriers of carbapenemase-producing 
K.  pneumoniae would be different. 
Environmental contamination plays 
a limited role in transmission of the 
organism (3). Caregivers should be 
aware that multidrug-resistant or-
ganisms of nosocomial origin can 
be transmitted in the community (5). 
Acquisition of such strains is prob-
ably of negligible importance in an 
otherwise healthy person. However, 
consequences may be different if the 
recipient of the strain is a debilitated 
patient.
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Alternatives to 
Ciproﬂ  oxacin Use 
for Enteric Fever, 
United Kingdom  
To the Editor: In cases of ty-
phoid and paratyphoid fever, it is of-
ten necessary to commence treatment 
before the results of laboratory sensi-
tivity tests are available. It is therefore 
important to be aware of optional drug 
therapies available because some or-
ganisms may be resistant to key anti-
microbial drugs. For typhoid and para-
typhoid, ciproﬂ   oxacin has become 
the ﬁ  rst-line drug of choice since the 
widespread emergence and spread of 
strains resistant to chloramphenicol, 
ampicillin, and trimethoprim (1).
The Laboratory of Enteric Patho-
gens (LEP) of the Health Protection 
Agency of England and Wales is the 
reference center for Salmonella enter-
ica serovars Typhi and Paratyphi A for 
the United Kingdom; as such, this lab-
oratory receives isolates from all cases 
of infection. Isolates are screened by 
breakpoint  for resistance to antimi-
crobial drugs at the following levels: 
chloramphenicol, 8 mg/L; ampicillin, 
8 mg/L; trimethoprim, 2 mg/L; cipro-
ﬂ  oxacin, 0.125 mg/L (decreased sus-
ceptibility); and 1.0 mg/L (high-level 
resistance), ceftriaxone, 1 mg/L, and 
cefotaxime, 1 mg/L. The levels for 
testing for resistance to chlorampheni-
col, ampicillin, trimethoprim, ceftri-
axone, and cefotaxime correspond to 
internationally accepted therapeutic 
levels for these antimicrobial agents. 
In contrast, the levels for ciproﬂ  oxa-
cin (0.125 and 1.0 mg/L) have been 
chosen after observations of treatment 
failures at levels when used at below 
the expected recommended serum 
concentrations (2,3). Since 2005, a 
proportion of isolates exhibiting de-
creased susceptibility and high-level 
resistance to ciproﬂ  oxacin have been 
tested for resistance to azithromycin 
by Etest (AB Biodisk, Solna, Swe-
den), using drug-sensitive strains of S. 
Typhi and S. Paratyphi A as controls. 
From January 2001 through De-
cember 2006, LEP reported 1,215 
cases of S. Typhi infection and 1,274 
cases of S. Paratyphi A infection. Of 
these,  ≈60% (1,493) reported recent 
travel abroad; India and Pakistan were 
the most frequently visited countries 
(4). Other cases were associated with 
persons who had a history of such trav-
el, but the numbers involved were dif-
ﬁ  cult to document accurately because 
of underreporting of foreign travel and 
other communication problems. 
For  S.  Typhi, the occurrence of 
isolates resistant to ciproﬂ  oxacin  at 
0.125 mg/L increased from 60 (35%) 
of 170 in 2001 to 169 (70%) of 240 
cases in 2006, with 4.8 (2%) of isolates 
in 2006 resistant at 1.0 mg/L (Table). 
The corresponding ﬁ  gures for S. Para-
typhi A were 58 (25%) of 232 cases 
in 2001, rising to 84% in 2004, with 
an incidence of 73% in 2006; 9% of 
these were resistant to ciproﬂ  oxacin at 
1.0 mg/L (Table). Moreover, in 2006, 
56 isolates of S. Typhi (23% of total) 
exhibited resistance to chlorampheni-
col, ampicillin, and trimethoprim, 54 
(96%) were also resistant to cipro-
ﬂ  oxacin at 0.125 mg/L. When tested 
for resistance to ceftriaxone and cefo-
taxime, none of the isolates (either S. 
Typhi or S. Paratyphi A) were resistant 
at 1.0 mg/L. 
Although the levels of resistance 
to ciproﬂ   oxacin were for the most 
part below that regarded as therapeu-
tic (MIC 0.25–1.0 mg/L), at least 21 
treatment failures have been docu-
mented since 2005. These ﬁ  ndings 
demonstrate that the efﬁ  cacy of cip-
roﬂ  oxacin  for  ﬁ   rst-line treatment of 
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